Your browser doesn't support javascript.
loading
DrugRep-HeSiaGraph: when heterogenous siamese neural network meets knowledge graphs for drug repurposing.
Ghorbanali, Zahra; Zare-Mirakabad, Fatemeh; Salehi, Najmeh; Akbari, Mohammad; Masoudi-Nejad, Ali.
Afiliação
  • Ghorbanali Z; Computational Biology Research Center (CBRC), Department of Mathematics and Computer Science, Amirkabir University of Technology, Tehran, Iran.
  • Zare-Mirakabad F; Computational Biology Research Center (CBRC), Department of Mathematics and Computer Science, Amirkabir University of Technology, Tehran, Iran. f.zare@aut.ac.ir.
  • Salehi N; School of Biological Science, Institute for Research in Fundamental Sciences (IPM), Tehran, Iran.
  • Akbari M; Computational Biology Research Center (CBRC), Department of Mathematics and Computer Science, Amirkabir University of Technology, Tehran, Iran.
  • Masoudi-Nejad A; Laboratory of Systems Biology and Bioinformatics (LBB), Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran.
BMC Bioinformatics ; 24(1): 374, 2023 Oct 03.
Article em En | MEDLINE | ID: mdl-37789314
ABSTRACT

BACKGROUND:

Drug repurposing is an approach that holds promise for identifying new therapeutic uses for existing drugs. Recently, knowledge graphs have emerged as significant tools for addressing the challenges of drug repurposing. However, there are still major issues with constructing and embedding knowledge graphs.

RESULTS:

This study proposes a two-step method called DrugRep-HeSiaGraph to address these challenges. The method integrates the drug-disease knowledge graph with the application of a heterogeneous siamese neural network. In the first step, a drug-disease knowledge graph named DDKG-V1 is constructed by defining new relationship types, and then numerical vector representations for the nodes are created using the distributional learning method. In the second step, a heterogeneous siamese neural network called HeSiaNet is applied to enrich the embedding of drugs and diseases by bringing them closer in a new unified latent space. Then, it predicts potential drug candidates for diseases. DrugRep-HeSiaGraph achieves impressive performance metrics, including an AUC-ROC of 91.16%, an AUC-PR of 90.32%, an accuracy of 84.63%, a BS of 0.119, and an MCC of 69.31%.

CONCLUSION:

We demonstrate the effectiveness of the proposed method in identifying potential drugs for COVID-19 as a case study. In addition, this study shows the role of dipeptidyl peptidase 4 (DPP-4) as a potential receptor for SARS-CoV-2 and the effectiveness of DPP-4 inhibitors in facing COVID-19. This highlights the practical application of the model in addressing real-world challenges in the field of drug repurposing. The code and data for DrugRep-HeSiaGraph are publicly available at https//github.com/CBRC-lab/DrugRep-HeSiaGraph .
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Reposicionamento de Medicamentos / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Reposicionamento de Medicamentos / COVID-19 Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2023 Tipo de documento: Article